Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) Price Target at $6.92

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) has received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.92.

CDLX has been the subject of a number of analyst reports. Bank of America downgraded Cardlytics from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Northland Capmk downgraded shares of Cardlytics from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 16th. Craig Hallum upgraded Cardlytics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 6th. Evercore ISI began coverage on shares of Cardlytics in a report on Friday, October 11th. They issued an "in-line" rating and a $4.00 target price on the stock. Finally, Northland Securities cut shares of Cardlytics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $7.00 to $5.00 in a report on Friday, August 16th.

Insider Activity at Cardlytics

In other news, CFO Alexis Desieno sold 25,118 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares in the company, valued at approximately $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Gupta sold 22,607 shares of the company's stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 68,691 shares of company stock worth $237,767. Company insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On Cardlytics

Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its stake in Cardlytics by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company's stock valued at $432,000 after purchasing an additional 1,774 shares during the last quarter. Canton Hathaway LLC lifted its position in shares of Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company's stock valued at $37,000 after buying an additional 2,200 shares during the last quarter. Check Capital Management Inc. CA boosted its stake in shares of Cardlytics by 10.4% during the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company's stock worth $162,000 after acquiring an additional 4,775 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Cardlytics by 32.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company's stock worth $63,000 after acquiring an additional 4,796 shares during the last quarter. Finally, Creative Planning raised its stake in Cardlytics by 35.4% in the 3rd quarter. Creative Planning now owns 29,537 shares of the company's stock valued at $95,000 after acquiring an additional 7,721 shares during the period. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Price Performance

Shares of CDLX traded down $0.07 during trading hours on Wednesday, reaching $3.98. The company had a trading volume of 326,719 shares, compared to its average volume of 1,190,797. The firm has a 50 day simple moving average of $3.86 and a 200-day simple moving average of $5.50. The company has a market capitalization of $202.26 million, a price-to-earnings ratio of -0.65 and a beta of 1.53. Cardlytics has a 12-month low of $2.89 and a 12-month high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40.

Cardlytics (NASDAQ:CDLX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million during the quarter, compared to analysts' expectations of $57.77 million. During the same quarter in the prior year, the business earned ($0.26) EPS. Cardlytics's quarterly revenue was down 15.1% compared to the same quarter last year. Research analysts expect that Cardlytics will post -1.52 earnings per share for the current year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.